# Brolucizumab Treatment Experience Study of Patients With nAMD in UK Routine Clinical Practice

> **NCT05112835** · — · TERMINATED · sponsor: **Novartis Pharmaceuticals** · enrollment: 302 (actual)

## Conditions studied

- Neovascular Age-related Macular Degeneration

## Interventions

- **OTHER:** brolucizumab

## Key facts

- **NCT ID:** NCT05112835
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** TERMINATED
- **Start date:** 2021-11-19
- **Primary completion:** 2022-09-08
- **Final completion:** 2022-09-08
- **Target enrollment:** 302 (ACTUAL)
- **Why stopped:** Sponsor decision
- **Last updated:** 2024-10-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05112835

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05112835, "Brolucizumab Treatment Experience Study of Patients With nAMD in UK Routine Clinical Practice". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05112835. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*